SCHEMBL29920601

SCHEMBL29920601

O=C(O)c1ccncc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 17/20 0.59
KDM6B O15054 8/20 0.59
KDM4D Q6B0I6 5/20 0.59
KDM4E B2RXH2 2/20 0.59
KDM4A O75164 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 1/20 0.59
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
KMT2A Q03164 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
KDM5A P29375 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
NAPRT Q6XQN6 1/20 0.43
APP P05067 1/20 0.42
GAA P10253 1/20 0.42
HCAR3 P49019 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480991 1.00 KDM4C (0.59) KDM4CKDM6BKDM4DKDM4EKDM4A
Hydrochloric Acid SCHEMBL2892062 0.98 KDM4C (0.57) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL933359 0.83 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL25207609 0.81 CCNC (0.43) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL31407215 0.81 CCNC (0.43) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL30694754 0.81 TDP1 (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL5700120 0.81 TDP1 (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL30694749 0.81 TDP1 (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL5208270 0.81 CCNC (0.43) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL782625 0.81 CCNC (0.43) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025026266-A1 COMPOUND AS LPAR1 ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 武汉朗来科技发展有限公司 2025-02-06 WO disclosed
US-12215107-B1 Pyrazino[1′,2′:1,5]pyrazolo[4,3-c] [2,6] naphthyridine compounds as CK2 inhibitors King Faisal University (SA) 2025-02-04 US disclosed
EP-4319756-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-02-14 EP disclosed
WO-2022217276-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12215107-B1 Pyrazino[1′,2′:1,5]pyrazolo[4,3-c] [2,6] naphthyridine compounds as CK2 inhibitors CSNK2A3, CKS2, CDK2 KDM4C 1750/4885KDM6B 3995/4885KDM4D 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.